Skip to NavigationSkip to content

Business Services

Industry veteran Dr David Setboun joins BrainStorm as Executive VP and COO

Published on: 03/04/20

BrainStorm Cell Therapeutics, a firm developing cellular therapies to tackle neurodegenerative diseases, has named industry Big Pharma veteran Dr David Setboun as its new Executive Vice President and Chief Operating Officer.

Dr Setboun has served for two decades at some of the biggest names in pharma. His most recent role was Vice President of Corporate Development, Strategy & Business at Life Biosciences, where he helped drive development of a range of vital commercial, operating and funding milestones.

Dr John C. McKew promoted to Chief Operating Officer at Lumos Pharma

Published on: 03/04/20

Lumos Pharma, Inc. has promoted Dr John McKew to the position of Chief Operating Officer effective 1 April 2020.

McKew is already Chief Scientific Officer and he will do both roles simultaneously. With his new role, he will lead Lumos’s clinical development plan as the company looks toward adding additional assets to its pipeline.

Steven T Gill returns to Alimera as VP, Thought Leader Engagement

Published on: 03/04/20

Ophthalmology specialist Alimera Sciences has announced that Steven T Gill is to return to the company in the newly created role of Vice President, Thought Leader Engagement.

Gill had previously served at Alimera as its Senior Director, Thought Leader Liaison, before leaving the company for Novartis, where he most recently held the position of Associate Director, Thought Leader Liaison at Novartis US.

Top Ten most popular articles on Pharmafile.com this week

COVID-19 coronavirus treatments dominate the news as the world looks for a vaccine. Johnson & Johnson announced that it has selected a candidate for a COVID-19 vaccine from potential constructs it has been investigating since January, and is targeting a Phase 1 study for September, while British American Tobacco has said it is developing a COVID-19 vaccine from tobacco plants.

FDA calls for heartburn drug Zantac to be pulled due to carcinogen concerns

Photo by zimt2003 on pixabay

The FDA is requesting that manufactures remove Zantac (ranitidine) from the market due to risks of it containing a carcinogen.

An ongoing investigation has determined that levels of contaminant in the heartburn medications increase over time and when stored at higher than normal temperatures and it poses a significant health risk. This contaminant is N-nitrosodimethylamine (NDMA) which a carcinogen that the FDA has been investigating in ranitidine since 2019.

FDA places no penalties on Novartis after Zolgensma data manipulation investigation

The FDA has concluded its investigation into Novartis and its data manipulation of the gene therapy Zolgensma, and has decided to place no penalties on the company.

In a statement, the FDA said it has “completed its review of the information and records of the inspection, the evidence collected, and the firm’s responses as well as the corrective actions.”

British American Tobacco creating coronavirus vaccine

Photo by sarangib

British American Tobacco has said it is developing a COVID-19 vaccine from tobacco plants.

The owner of famous cigarette brands, such as Lucky Strike, Dunhill, Rothmans and Benson & Hedges, the company is using its biotech subsidiary Kentucky BioProcessing to work on developing a vaccine.

The April 2020 issue of Pharmafocus is available to read free online now!

The latest monthly edition of Pharmafocus, the April 2020 issue, is available to read for free online now!

There’s one big story on everyone’s mind, and with the whirlwind of information (and misinformation) around the COVID-19 pandemic, it’s easy to get disorientated. The latest issue of Pharmafocus aims to cut through that by providing a blow-by-blow account of some of the key milestones on the journey to where we are today.

People or profit: What is the best system to regulate drug prices?

Published on 30/03/20 at 01:01pm

Conor Kavanagh investigates the role state healthcare institutions play in negotiating drug prices, and what steps can be taken for a more mutually beneficial relationship to exist between pharmaceutical companies and governments when it comes to the pricing of drug products.

Top Ten most popular articles on Pharmafile.com this week

The COVID-19 global pandemic continues to dominate the news cycle. The first clinical trial using danoprevir (Ganovo) in treating COVID-19 has released its results, showing that it is safe and well tolerated in patients, while Dr Anthony Fauci, the Director of the National Institute of Allergy and Infectious Disease in the US, said that people between the ages of 20 and 44 have been more seriously impacted by the coronavirus in Europe and the US compared to China.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches